Sugi Predict

Sugi Predict / Compounds / SCHEMBL8107311

SCHEMBL8107311

SCHEMBL8107311

CCOC(=O)c1c(N)ccc(F)c1F

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 5/20 0.47
▸ HSD17B10 Q99714 5/20 0.47
▸ HPGD P15428 4/20 0.47
▸ SMN1; SMN2 Q16637 4/20 0.47
▸ MAPT P10636 4/20 0.47
▸ GAA P10253 3/20 0.47
▸ CA12 O43570 1/20 0.47
▸ CA1 P00915 1/20 0.47
▸ CA2 P00918 1/20 0.47
▸ CA7 P43166 1/20 0.47
▸ CA9 Q16790 1/20 0.47
▸ CA14 Q9ULX7 1/20 0.47
▸ LMNA P02545 1/20 0.46
▸ CYP1A2 P05177 1/20 0.46
▸ CYP3A4 P08684 1/20 0.46
▸ MAOA P21397 1/20 0.46
▸ PRKCZ Q05513 4/20 0.46
▸ GRM6 O15303 1/20 0.46
▸ FHIT P49789 1/20 0.44
▸ NPSR1 Q6W5P4 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL687729 0.98 ALDH1A1 (0.46) ALDH1A1HSD17B10HPGDSMN1; SMN2MAPT
SCHEMBL5431033 0.87 ALDH1A1 (0.47) ALDH1A1HSD17B10HPGDSMN1; SMN2MAPT
SCHEMBL1997194 0.86 CA12 (0.53) ALDH1A1HSD17B10HPGDSMN1; SMN2MAPT
SCHEMBL8278988 0.85 ALDH1A1 (0.46) ALDH1A1HSD17B10HPGDSMN1; SMN2MAPT
Hydrochloric Acid SCHEMBL4934877 0.84 ALDH1A1 (0.45) ALDH1A1HSD17B10HPGDSMN1; SMN2MAPT
SCHEMBL9573869 0.84 PRKCZ (0.47) ALDH1A1HSD17B10HPGDSMN1; SMN2MAPT
SCHEMBL939282 0.83 ALDH1A1 (0.47) ALDH1A1HSD17B10HPGDSMN1; SMN2MAPT
SCHEMBL22980415 0.83 PRKCZ (0.51) ALDH1A1HSD17B10HPGDSMN1; SMN2MAPT
SCHEMBL29037249 0.81 TSHR (0.52) ALDH1A1HSD17B10HPGDSMN1; SMN2MAPT
SCHEMBL30724527 0.81 ALDH1A1 (0.43) ALDH1A1HSD17B10HPGDMAPTGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11993585-B2 Poly-ADP ribose polymerase (PARP) inhibitors MITOBRIDGE, INC. (US) 2024-05-28 — — US disclosed
CN-110167926-B Poly-ADP ribose polymerase (PARP) inhibitors 米托布里奇公司 2022-09-13 — — CN disclosed
US-20220033380-A1 POLY-ADP RIBOSE POLYMERASE (PARP) INHIBITORS Astellas Engineered Small Molecules US, Incorporated 2022-02-03 — — US disclosed
US-20220033380-A1 POLY-ADP RIBOSE POLYMERASE (PARP) INHIBITORS Astellas Engineered Small Molecules US, Incorporated 2022-02-03 — — US disclosed
US-11034670-B2 Poly-ADP ribose polymerase (PARP) inhibitors MITOBRIDGE, INC. (US) 2021-06-15 — — US disclosed
US-11034670-B2 Poly-ADP ribose polymerase (PARP) inhibitors MITOBRIDGE, INC. (US) 2021-06-15 — — US disclosed
EP-3562822-B1 POLY-ADP RIBOSE POLYMERASE (PARP) INHIBITORS MITOBRIDGE INC (US) 2021-03-10 — — EP disclosed
EP-3562822-B1 POLY-ADP RIBOSE POLYMERASE (PARP) INHIBITORS MITOBRIDGE INC (US) 2021-03-10 — — EP disclosed
US-20200071299-A1 POLY-ADP RIBOSE POLYMERASE (PARP) INHIBITORS Astellas Engineered Small Molecules US, Incorporated 2020-03-05 — — US disclosed
US-20200071299-A1 POLY-ADP RIBOSE POLYMERASE (PARP) INHIBITORS Astellas Engineered Small Molecules US, Incorporated 2020-03-05 — — US disclosed
EP-3562822-A1 POLY-ADP RIBOSE POLYMERASE (PARP) INHIBITORS Mitobridge, Inc. (US) 2019-11-06 — — EP disclosed
CN-110167926-A POLY-ADP RIBOSE POLYMERASE (PARP) INHIBITORS 米托布里奇公司 2019-08-23 — — CN disclosed
WO-2018125961-A1 POLY-ADP RIBOSE POLYMERASE (PARP) INHIBITORS MITOBRIDGE, INC. (US) 2018-07-05 — — WO disclosed
WO-2018125961-A1 POLY-ADP RIBOSE POLYMERASE (PARP) INHIBITORS MITOBRIDGE, INC. (US) 2018-07-05 — — WO disclosed
US-20110009435-A1 HETERO BICYCLIC CARBOXAMIDE DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS PFIZER, INC. (US) 2011-01-13 — — US disclosed
US-20110009435-A1 HETERO BICYCLIC CARBOXAMIDE DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS PFIZER, INC. (US) 2011-01-13 — — US disclosed
WO-2008149191-A1 HETERO BICYCLIC CARBOXAMIDE DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS PFIZER INC. (US) 2008-12-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220033380-A1 POLY-ADP RIBOSE POLYMERASE (PARP) INHIBITORS PARP1, PARP2, PARP11 ALDH1A1 203/4885HSD17B10 1012/4885HPGD 139/4885
US-11993585-B2 Poly-ADP ribose polymerase (PARP) inhibitors PARP1, PARP2, PARP11 ALDH1A1 203/4885HSD17B10 1012/4885HPGD 139/4885
US-11034670-B2 Poly-ADP ribose polymerase (PARP) inhibitors PARP1, PARP2, PARP11 ALDH1A1 203/4885HSD17B10 1012/4885HPGD 139/4885
US-20110009435-A1 HETERO BICYCLIC CARBOXAMIDE DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS CNR2, CYP2C9, CYP2C8 ALDH1A1 944/4885HSD17B10 1473/4885HPGD 135/4885
US-20200071299-A1 POLY-ADP RIBOSE POLYMERASE (PARP) INHIBITORS PARP1, PARP2, PARP11 ALDH1A1 203/4885HSD17B10 1012/4885HPGD 139/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.